Wells Fargo downgraded AptarGroup from Overweight to Equal Weight and set a new price target of $133.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/6/2026 | $133.00 | Overweight → Equal Weight | Wells Fargo |
| 11/3/2025 | Outperform → Mkt Perform | William Blair | |
| 9/4/2025 | $220.00 | Overweight | KeyBanc Capital Markets |
| 1/7/2025 | $200.00 | Outperform | Raymond James |
| 1/6/2025 | $173.00 | Buy → Neutral | BofA Securities |
| 10/14/2024 | $155.00 → $215.00 | Hold → Buy | Jefferies |
| 4/29/2024 | Mkt Perform → Outperform | William Blair | |
| 1/3/2024 | $125.00 → $150.00 | Neutral → Outperform | Robert W. Baird |
8-K - APTARGROUP, INC. (0000896622) (Filer)
SCHEDULE 13G/A - APTARGROUP, INC. (0000896622) (Subject)
10-K - APTARGROUP, INC. (0000896622) (Filer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that Gael Touya, a seasoned global executive with more than 30 years of experience at the company, most recently as Aptar Pharma President, has been appointed President and Chief Executive Officer, effective September 1, 2026. He will succeed Stephan B. Tanda, who has served as President and Chief Executive Officer since 2017. Stephan is expected to continue to work closely with Gael and the Board as an advisor through the end of the year to help ensure a seamless transition as the company enters its next phase of growth. Stephan intends to reti
Supporting advancement of complex intranasal therapies through clinical development AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that its proprietary nasal delivery system is being utilized in LTR Pharma Limited's (ASX:LTP) Phase II clinical study of SPONTAN®, an investigational intranasal spray under development for the treatment of erectile dysfunction. This milestone reflects Aptar Pharma's continued commitment to supporting intranasal drug delivery technologies and supporting the development of innovative, patient-centric therapies. This press release features multimedia. View the f
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery and consumer product dispensing, dosing and protection technologies, today announced that it will present at two upcoming investor conferences: The Bank of America Securities 2026 Global Agriculture and Materials Conference in Ft. Lauderdale, FL on Wednesday, February 25, 2026. Stephan Tanda, President and CEO, will present at 9:45 a.m. Eastern Standard Time. The Raymond James 2026 Institutional Investors Conference on Tuesday, March 3, 2026. Vanessa Kanu, Executive Vice President and CFO, will present at 1:05 p.m. Eastern Standard Time. A live audio webcast and presentation materials will be available in the "Investors"
Wells Fargo downgraded AptarGroup from Overweight to Equal Weight and set a new price target of $133.00
William Blair downgraded AptarGroup from Outperform to Mkt Perform
KeyBanc Capital Markets initiated coverage of AptarGroup with a rating of Overweight and set a new price target of $220.00
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that Gael Touya, a seasoned global executive with more than 30 years of experience at the company, most recently as Aptar Pharma President, has been appointed President and Chief Executive Officer, effective September 1, 2026. He will succeed Stephan B. Tanda, who has served as President and Chief Executive Officer since 2017. Stephan is expected to continue to work closely with Gael and the Board as an advisor through the end of the year to help ensure a seamless transition as the company enters its next phase of growth. Stephan intends to reti
Aptar Names Vanessa Kanu, A Finance Veteran with Over 25 Years of Experience, as Next CFO AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that Bob Kuhn, Executive Vice President and Chief Financial Officer (CFO) since 2008, has decided to retire at the end of this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725873916/en/(Left to right) Bob Kuhn, Executive Vice President and Chief Financial Officer since 2008, has decided to retire at the end of 2024; Vanessa Kanu will become Executive Vice President and CFO on January 1, 2025,
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that Sarah Glickman, an accomplished leader with more than 30 years of global financial and operational experience, has joined its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230905451175/en/Sarah Glickman Joins Aptar's Board of Directors (Photo: Aptar) "We are pleased to welcome Sarah Glickman to our Board of Directors. Sarah's extensive knowledge of all aspects of corporate finance coupled with her global operational experience, including in the pharmaceutical industry
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery and consumer product dispensing, dosing and protection technologies, today reported the following fourth quarter results for the period ended December 31, 2025, as compared to the corresponding period of the last fiscal year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260205227722/en/Photo: Aptar Fourth Quarter 2025 Highlights (Compared to the prior year quarter; see Non-GAAP section for full definitions; see reconciliation for Non-GAAP measures) Reported sales increased 14% and core sales increased 5%—all three segments delivered core sales growth Reporte
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery and consumer product dispensing, dosing and protection technologies, today announced that the Board declared a quarterly cash dividend of $0.48 per share. The payment date is February 25, 2026, to stockholders of record as of February 4, 2026. As previously announced, Aptar will hold a conference call on Friday, February 6, 2026, at 8:00 a.m. Central Time to discuss the Company's fourth quarter and year-end results for 2025. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investors page at www.aptar.com. A replay of the conference call can also be accessed fo
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery and consumer product dispensing, dosing and protection technologies, today announced the dates and times of quarterly conference calls for the year. Any updates to these dates or times will be communicated in subsequent press releases. Quarterly Conference Calls Press Release(1) Conference Call(2) 4th Quarter and Annual 2025 Results February 5, 2026 February 6, 2026, at 8:00 a.m. CT 1st Quarter 2026 Results April 30, 2026 May 1, 2026, at 8:00 a.m. CT 2nd Quarter 2026 Results July 30, 2026 July 31, 2026, at 8:00 a.m. CT 3rd Quarter 2026 Results
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)